Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $256.82 million. The enterprise value is $42.35 million.
| Market Cap | 256.82M |
| Enterprise Value | 42.35M |
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 111.66 million shares outstanding. The number of shares has increased by 4.69% in one year.
| Current Share Class | 109.77M |
| Shares Outstanding | 111.66M |
| Shares Change (YoY) | +4.69% |
| Shares Change (QoQ) | -0.76% |
| Owned by Insiders (%) | 3.86% |
| Owned by Institutions (%) | 74.78% |
| Float | 87.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 21.94 |
| PB Ratio | 0.81 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.17.
| Current Ratio | 7.26 |
| Quick Ratio | 7.03 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -100.65 |
Financial Efficiency
Return on equity (ROE) is -5.04% and return on invested capital (ROIC) is -33.04%.
| Return on Equity (ROE) | -5.04% |
| Return on Assets (ROA) | -30.23% |
| Return on Invested Capital (ROIC) | -33.04% |
| Return on Capital Employed (ROCE) | -49.96% |
| Weighted Average Cost of Capital (WACC) | 6.20% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$79,960 |
| Employee Count | 202 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RCKT has paid $8.68 million in taxes.
| Income Tax | 8.68M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.30% in the last 52 weeks. The beta is 0.49, so RCKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | -30.30% |
| 50-Day Moving Average | 2.71 |
| 200-Day Moving Average | 3.39 |
| Relative Strength Index (RSI) | 41.47 |
| Average Volume (20 Days) | 1,646,823 |
Short Selling Information
The latest short interest is 16.28 million, so 14.58% of the outstanding shares have been sold short.
| Short Interest | 16.28M |
| Short Previous Month | 15.05M |
| Short % of Shares Out | 14.58% |
| Short % of Float | 18.57% |
| Short Ratio (days to cover) | 6.83 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -190.43M |
| Pretax Income | -7.48M |
| Net Income | -16.15M |
| EBITDA | -181.93M |
| EBIT | -190.43M |
| Earnings Per Share (EPS) | -$0.14 |
Balance Sheet
The company has $269.51 million in cash and $55.04 million in debt, with a net cash position of $214.47 million or $1.92 per share.
| Cash & Cash Equivalents | 269.51M |
| Total Debt | 55.04M |
| Net Cash | 214.47M |
| Net Cash Per Share | $1.92 |
| Equity (Book Value) | 326.72M |
| Book Value Per Share | 2.93 |
| Working Capital | 239.73M |
Cash Flow
In the last 12 months, operating cash flow was -$158.90 million and capital expenditures -$332,000, giving a free cash flow of -$159.23 million.
| Operating Cash Flow | -158.90M |
| Capital Expenditures | -332,000 |
| Depreciation & Amortization | 8.50M |
| Net Borrowing | 33.97M |
| Free Cash Flow | -159.23M |
| FCF Per Share | -$1.43 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.69% |
| Shareholder Yield | -4.69% |
| Earnings Yield | -6.24% |
| FCF Yield | -61.73% |
Analyst Forecast
The average price target for RCKT is $9.09, which is 295.26% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.09 |
| Price Target Difference | 295.26% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |